With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.129722-25-4,7-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2(1H)-one,as a common compound, the synthetic route is as follows.
A mixture of compound 75 (1.2 g) in 4M HCl/dioxane (100 mL) was stirred at RT for 2 h. The solvent was removed under reduced pressure and the residue was dried under vacuum at 50 0C to afford the HCl salt of compound 75 (1.2 g) as a light-yellow solid. 1H-NMR (300 MHz, DMSO-de): delta 1.82-1.92 (m, 4H), 3.12-3.26 (m, 6H)3 3.45 (d, J = 9.4 Hz52H), 3.62 (d, J = 8.5 Hz, 2H), 4.07 (t, J = 5.5 Hz, 2H), 6.32 (d, J = 9.4 Hz, IH), 6.82 (dd, J1 = 4.5 Hz, J2 = 2.4 Hz, 2H), 7.22 (dd, J1 = 6.7 Hz, J2= 2.6 Hz, IH), 7.34-7.41 (m, 2H), 7.58 (d, J = 9.6 Hz, IH), 7.83 (d, J = 9.6 Hz, IH), 10.52 (bs, IH), 11.69 (bs, IH). 13C-NMR (75 MHz, DMSO-de): delta 20.84, 26.46, 48.44, 51.81, 55.84, 67.65, 99.33, 111.47, 114.09, 119.22, 120.53, 126.01, 126.72, 129.37, 129.99, 133.42, 140.76, 141.30, 150.18, 160.94, 162.94. HPLC (method: 20 mm C 18-RP column; mobile phase: 2-95% ACN + 0.1% formic acid in 3.3 min with 1.7 min hold at 95% ACN, Wavelength: 254 ran): retention time: 2.74 min. MS (M + H+): 446.1., 129722-25-4
129722-25-4 7-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2(1H)-one 10114519, apiperazines compound, is more and more widely used in various fields.
Reference£º
Patent; CONCERT PHARMACEUTICALS INC.; WO2008/24481; (2008); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics